company background image
ARAV logo

Aravive NasdaqGS:ARAV Stock Report

Last Price

US$0.04

Market Cap

US$2.9m

7D

-17.3%

1Y

-97.6%

Updated

29 Jan, 2024

Data

Company Financials

ARAV Stock Overview

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States.

ARAV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Aravive, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aravive
Historical stock prices
Current Share PriceUS$0.04
52 Week HighUS$2.46
52 Week LowUS$0.04
Beta2.19
11 Month Change-67.58%
3 Month Change-69.30%
1 Year Change-97.63%
33 Year Change-99.22%
5 Year Change-99.06%
Change since IPO-99.98%

Recent News & Updates

Recent updates

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Aravive Q2 GAAP EPS misses, revenue beats

Aug 11

Aravive appoints Robert Geller as CMO

Jul 05

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

May 15
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Nov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Jun 25
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive EPS beats by $0.01, misses on revenue

May 06

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

Shareholder Returns

ARAVUS BiotechsUS Market
7D-17.3%5.5%1.2%
1Y-97.6%13.7%22.3%

Return vs Industry: ARAV underperformed the US Biotechs industry which returned 6.5% over the past year.

Return vs Market: ARAV underperformed the US Market which returned 17.6% over the past year.

Price Volatility

Is ARAV's price volatile compared to industry and market?
ARAV volatility
ARAV Average Weekly Movement19.5%
Biotechs Industry Average Movement10.5%
Market Average Movement5.8%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.8%

Stable Share Price: ARAV's share price has been volatile over the past 3 months.

Volatility Over Time: ARAV's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200823n/aaravive.com

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.

Aravive, Inc. Fundamentals Summary

How do Aravive's earnings and revenue compare to its market cap?
ARAV fundamental statistics
Market capUS$2.95m
Earnings (TTM)-US$39.85m
Revenue (TTM)US$6.99m

0.4x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARAV income statement (TTM)
RevenueUS$6.99m
Cost of RevenueUS$53.39m
Gross Profit-US$46.39m
Other Expenses-US$6.55m
Earnings-US$39.85m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin-663.34%
Net Profit Margin-569.73%
Debt/Equity Ratio0%

How did ARAV perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.